Advances in live biotherapeutic products and key formulation challenges Live Biotherapeutic Products (LBPs) are living bacterial drugs that can be used to prevent or treat certain human diseases. This rising class of pharmaceutical drugs is […]
Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome […]
On-Demand Webinar Learn about utilizing next-generation sequencing (NGS) to analyze the genetic diversity and function of complex microbial communities. Compared to culture-based methods, powerful techniques like metagenomics and metatranscriptomics can provide a more comprehensive and […]
GN Corporation’s Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne […]
Microbes were the only life form on Earth for most of the history of our planet. Even today, they still make up the majority of species that are vital to the health of our planet. […]
Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex […]
ProDigest has been awarded a contract to provide a SHIME® (Simulator of Human Intestinal Microbial Ecosystem) technology platform for full gut simulation to the US Food and Drug Administration (FDA), National Center for Toxicological Research. […]
32 Biosciences, pronounced “Three Squared Biosciences,” announces its emergence from stealth mode, with new microbiome diagnostic management tools and microbiome-based interventions. The company intends to revolutionize healthcare with its novel approach to gut microbiome medicine. […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today reports topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT. In this patient population, infections are […]
dsm-firmenich, a global innovator in health, nutrition and beauty, today announced the successful approval of its human milk oligosaccharide (HMO): 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2′-fucosyllactose (LNFP-I/2′-FL) mixture as novel food ingredients in the United Kingdom […]
Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more. This continued support from existing backers […]